Morales T G, Bhattacharyya A, Johnson C, Sampliner R E
Department of Medicine, Arizona Health Sciences Center, Tucson, USA.
Am J Gastroenterol. 1997 Oct;92(10):1818-22.
Barrett's esophagus has been associated with adenocarcinoma of the esophagogastric junction and gastric cardia. The purpose of this study was to determine whether patients with Barrett's esophagus have a higher prevalence of intestinal metaplasia involving the gastric cardia than those without Barrett's esophagus.
Two groups of patients were compared for the prevalence of intestinal metaplasia of the gastric cardia. Group 1 included 50 patients with well-defined Barrett's esophagus who were being followed in an endoscopic surveillance program. Group 2 consisted of 104 individuals participating in a separate study identifying the prevalence of cardia intestinal metaplasia in patients undergoing elective upper endoscopy. Both groups had biopsy specimens taken from the gastric cardia. Eleven patients in group 2 were found to have Barrett's esophagus and were excluded from the analysis. Histological evidence of intestinal metaplasia was defined as specialized columnar epithelium containing goblet cells staining with Alcian blue at pH 2.5.
The prevalence of cardia intestinal metaplasia in the 50 patients in group 1 (Barrett's esophagus) was 22%, whereas the prevalence in the 93 patients in group 2 (no Barrett's esophagus) was 24%, which was not a statistically significant difference. A significant difference between groups still could not be identified when the results were examined with regard to equal number of biopsy specimens taken. None of the patients in either group had dysplasia identified within the cardia intestinal metaplasia.
Patients with Barrett's esophagus do not have a higher prevalence of intestinal metaplasia of the gastric cardia than those presenting for routine endoscopy. Although intestinal metaplasia of the gastric cardia is a relatively common finding, dysplasia is uncommon. Therefore, we suggest that screening biopsy specimens of the gastric cardia in patients with Barrett's esophagus be limited to study protocols at this time. In addition, we believe that these data raise the question of whether a true association exists between Barrett's esophagus and gastric cardia cancer.
巴雷特食管与食管胃交界腺癌和胃贲门癌相关。本研究的目的是确定巴雷特食管患者胃贲门肠化生的患病率是否高于无巴雷特食管的患者。
比较两组患者胃贲门肠化生的患病率。第1组包括50例在接受内镜监测项目的明确巴雷特食管患者。第2组由104名参与另一项研究的个体组成,该研究确定了接受选择性上消化道内镜检查患者的贲门肠化生患病率。两组均取胃贲门活检标本。第2组中有11例患者被发现患有巴雷特食管,被排除在分析之外。肠化生的组织学证据定义为在pH 2.5时含有经阿尔辛蓝染色的杯状细胞的特殊柱状上皮。
第1组(巴雷特食管)的50例患者中贲门肠化生的患病率为22%,而第2组(无巴雷特食管)的93例患者中患病率为24%,差异无统计学意义。当检查相同数量活检标本的结果时,两组之间仍未发现显著差异。两组中均未在贲门肠化生中发现发育异常。
巴雷特食管患者胃贲门肠化生的患病率并不高于接受常规内镜检查的患者。虽然胃贲门肠化生是一个相对常见的发现,但发育异常并不常见。因此,我们建议目前巴雷特食管患者胃贲门的筛查活检标本应限于研究方案。此外,我们认为这些数据提出了巴雷特食管与胃贲门癌之间是否存在真正关联的问题。